Your trusted source for investing success

Tag: gross proceeds

Avinger Announces Closing of $18 Million Underwritten Public Offering

Avinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced the closing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross proceeds of approximately $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger.

As

Motus GI Announces Closing of Initial Public Offering

Motus GI (NASDAQ: MOTS) a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today the closing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $5.00 per share, with gross proceeds of $17.5 million. Additionally, Motus has granted the

AIT Therapeutics Announces $9.82 Million Private Placement

AIT Therapeutics (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that it has completed a private placement with a select group of investors, which, assuming the exercise of the Tranche A portion

Moleculin Announces Pricing of $9 Million Registered Direct Offering

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, announced that it has entered into a definitive agreement with institutional investors

Amicus Therapeutics Prices Underwritten Offering of Common Stock

Amicus Therapeutics (Nasdaq:FOLD) announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are expected to be $300 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus.

As quoted in the press

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the closing of an underwritten public offering of 3,382,352 shares of its common stock, offered at a price of $34.00 per share to the public, which includes the exercise in

Burcon Announces Completion of Rights Offering

Burcon NutraScience (NASDAQ:BUR) is pleased to announce the completion of its rights offering, which expired at 5:00pm (EST) on February 13, 2018. The Rights Offering will result in the issuance of 6,114,361 common shares of Burcon at a price of $0.57 per share for gross proceeds of approximately $3.49 million.

As quoted in the press

Avinger Announces Pricing of $18 Million Underwritten Public Offering

Avinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger.

As

Levon Closes $900,000 Private Placement

Levon Closes $900,000 Private Placement

Levon Resources Ltd. (TSX:LVN) (“Levon” or “the Company”) announces that it has amended and closed its previously announced non-brokered private placement (the “Placement”) through the issuance of units of the Company (“Units”) at a price of C$0.35 per Unit, for total gross proceeds of $899,925.

West High Yield Updates Closing of Private Placement

West High Yield Updates Closing of Private Placement

On January 31, 2018, West High Yield (W.H.Y.) Resources Ltd. (“West High Yield” or the “Company”) (TSX-V:WHY) announced that it had completed the first tranche of its previously announced non-brokered private placement of units (“Units”) by issuing an aggregate of 2,721,581 Units at a price of $0.35 per Unit for

Adverum Biotechnologies Announces Closing of $69 Million Public Offering

Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the closing of its previously announced underwritten public offering of its common stock.  Adverum Biotechnologies sold 10,222,235 shares of its common stock, including 1,333,335 shares pursuant to the full exercise

Golden Predator Completes $8.38 Million Financing

Golden Predator Completes $8.38 Million Financing

Golden Predator Mining Corp. (TSXV:GPY) (the “Company” or “Golden Predator”) is pleased to announce that it has completed its previously announced overnight marketed offering, including a partial exercise of the underwriter’s over-allotment option (the “Offering”).

10+ Gold Stocks to Watch

Stocks.
Expert Insights.
Industry Stats.



Give me my free report!
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Avinger Announces Closing of Million Underwritten Public Offering

URL: https://investingnews.com/daily/life-science-investing/medical-device-investing/avinger-announces-closing-18-million-underwritten-public-offering/